357 related articles for article (PubMed ID: 32315234)
1. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
Kongpetch S; Jusakul A; Lim JQ; Ng CCY; Chan JY; Rajasegaran V; Lim TH; Lim KH; Choo SP; Dima S; Popescu I; Duda DG; Kukongviriyapan V; Khuntikeo N; Pairojkul C; Rozen SG; Tan P; Teh BT
JCO Glob Oncol; 2020 Apr; 6():628-638. PubMed ID: 32315234
[TBL] [Abstract][Full Text] [Related]
2. Genomic and transcriptional alterations of cholangiocarcinoma.
Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
[TBL] [Abstract][Full Text] [Related]
3. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
[TBL] [Abstract][Full Text] [Related]
4.
Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
[TBL] [Abstract][Full Text] [Related]
5. Risk biomarkers for assessment and chemoprevention of liver fluke-associated cholangiocarcinoma.
Yongvanit P; Pinlaor S; Loilome W
J Hepatobiliary Pancreat Sci; 2014 May; 21(5):309-15. PubMed ID: 24408859
[TBL] [Abstract][Full Text] [Related]
6. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Jusakul A; Cutcutache I; Yong CH; Lim JQ; Huang MN; Padmanabhan N; Nellore V; Kongpetch S; Ng AWT; Ng LM; Choo SP; Myint SS; Thanan R; Nagarajan S; Lim WK; Ng CCY; Boot A; Liu M; Ong CK; Rajasegaran V; Lie S; Lim AST; Lim TH; Tan J; Loh JL; McPherson JR; Khuntikeo N; Bhudhisawasdi V; Yongvanit P; Wongkham S; Totoki Y; Nakamura H; Arai Y; Yamasaki S; Chow PK; Chung AYF; Ooi LLPJ; Lim KH; Dima S; Duda DG; Popescu I; Broet P; Hsieh SY; Yu MC; Scarpa A; Lai J; Luo DX; Carvalho AL; Vettore AL; Rhee H; Park YN; Alexandrov LB; Gordân R; Rozen SG; Shibata T; Pairojkul C; Teh BT; Tan P
Cancer Discov; 2017 Oct; 7(10):1116-1135. PubMed ID: 28667006
[TBL] [Abstract][Full Text] [Related]
7. Aberrant GLUT1 Expression Is Associated With Carcinogenesis and Progression of Liver Fluke-associated Cholangiocarcinoma.
Thamrongwaranggoon U; Sangkhamanon S; Seubwai W; Saranaruk P; Cha'on U; Wongkham S
In Vivo; 2021; 35(1):267-274. PubMed ID: 33402473
[TBL] [Abstract][Full Text] [Related]
8. Cholangiocarcinoma.
Brindley PJ; Bachini M; Ilyas SI; Khan SA; Loukas A; Sirica AE; Teh BT; Wongkham S; Gores GJ
Nat Rev Dis Primers; 2021 Sep; 7(1):65. PubMed ID: 34504109
[TBL] [Abstract][Full Text] [Related]
9. Genetic Differentiation of
Buathong S; Phaiphilai K; Ruang-Areerate T; Sitthichot N; Thita T; Mungthin M; Suwannahitatorn P
Am J Trop Med Hyg; 2020 Sep; 103(3):1118-1124. PubMed ID: 32588808
[TBL] [Abstract][Full Text] [Related]
10. Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma: Association of diabetes mellitus and cholangiocarcinoma.
Saengboonmee C; Seubwai W; Wongkham C; Wongkham S
Cancer Epidemiol; 2015 Jun; 39(3):274-8. PubMed ID: 25910864
[TBL] [Abstract][Full Text] [Related]
11. PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.
Loilome W; Yooyuen S; Namwat N; Sithithaworn P; Puapairoj A; Kano J; Noguchi M; Miwa M; Yongvanit P
Tumour Biol; 2012 Dec; 33(6):2289-98. PubMed ID: 22922884
[TBL] [Abstract][Full Text] [Related]
12. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
[TBL] [Abstract][Full Text] [Related]
13. Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection.
Buckarma E; De La Cruz G; Truty M; Nagorney D; Cleary S; Kendrick M; Borad M; Graham RP; Gores G; Smoot R
HPB (Oxford); 2022 Oct; 24(10):1748-1756. PubMed ID: 35718679
[TBL] [Abstract][Full Text] [Related]
14. Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator.
Silakit R; Loilome W; Yongvanit P; Chusorn P; Techasen A; Boonmars T; Khuntikeo N; Chamadol N; Pairojkul C; Namwat N
J Hepatobiliary Pancreat Sci; 2014 Dec; 21(12):864-72. PubMed ID: 25131257
[TBL] [Abstract][Full Text] [Related]
15. Roles of liver fluke infection as risk factor for cholangiocarcinoma.
Sithithaworn P; Yongvanit P; Duenngai K; Kiatsopit N; Pairojkul C
J Hepatobiliary Pancreat Sci; 2014 May; 21(5):301-8. PubMed ID: 24408775
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
[TBL] [Abstract][Full Text] [Related]
17. Expected rate of liver fluke-related cholangiocarcinoma in endemic area of liver fluke with antiparasitic drug distribution program for disease control in Thailand.
Wiwanitkit V
J Cancer Res Ther; 2022; 18(4):927-930. PubMed ID: 36149142
[TBL] [Abstract][Full Text] [Related]
18. Role of molecular genetics in the clinical management of cholangiocarcinoma.
Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
[TBL] [Abstract][Full Text] [Related]
19. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Arai Y; Totoki Y; Hosoda F; Shirota T; Hama N; Nakamura H; Ojima H; Furuta K; Shimada K; Okusaka T; Kosuge T; Shibata T
Hepatology; 2014 Apr; 59(4):1427-34. PubMed ID: 24122810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
